This news really had us doing a double take.
But, basically, the United Nations World Health Organization (WHO) is asking you for your experience and information on canabidiol (CBD). The US Food and Drug Administration has put out a call for comments (from the public!) in this Thursday’s Federal Register. All data collected will lead them in assigning proper designation for the substance. Commenters have until September 13, 2017 to submit and can do so at this federal site.
After so much back and forth in legalization among the states and the Feds and the CBD versus THC nonsense, this is surprisingly good news! Just days ago, Senator Cory Booker uses Facebook Live to call for sweeping Federal legalization of cannabis, and now WHO is considering serious medicinal review of CBD – and is actually asking us for input on the matter. Progress has arrived, our fellow green activists!
CBD is actually on the list of 17 substances for consideration. Six types of the synthetic opioid fentanyl, five synthetic cannabinoid agonists (of the K2 and Spice type), and the psychoactive muscle relaxant ketamine are also up for review. Ketamine is another shocker, as it is reported to help with depression.
Even as cannabis sits under Schedule 1 classification, FDA Deputy Commissioner Anna K. Abram, who sent out the notice thursday morning, stated that “CBD has been shown to be beneficial in experimental models of several neurological disorders, including those of seizure and epilepsy.” We don’t wonder what all these comments will have to say, as CBD is ripe for helping public health in the best ways possible – but let’s just hope the world listens.
***SUBMIT your CBD comments here!
For further information:
James Hunter FDA’s Center for Drug Evaluation and Research Controlled Substance Staff
301-796-3156 ; email@example.com.